Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

76.72USD
7 Dec 2018
Change (% chg)

$-1.65 (-2.11%)
Prev Close
$78.37
Open
$78.27
Day's High
$78.29
Day's Low
$76.10
Volume
4,552,233
Avg. Vol
3,279,455
52-wk High
$80.18
52-wk Low
$52.83

Select another date:

Wed, Nov 28 2018

Photo

Merck raised prices five drugs including Keytruda in November

NEW YORK Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

Merck raised prices five drugs including Keytruda in November

NEW YORK, Nov 28 Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

Merck drug Keytruda succeeds in late-stage esophageal cancer trial

Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.

UPDATE 1-Merck drug Keytruda succeeds in late-stage esophageal cancer trial

Nov 14 Merck & Co's blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.

Merck cancer drug Keytruda succeeds in late-stage trial

Nov 14 U.S. drugmaker Merck & Co said on Wednesday its blockbuster cancer drug Keytruda met the main goal of a late-stage trial, of extending the lives of patients with cancers of the digestive tract.

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Merck says to retain animal health business as part of company

Oct 25 Merck & Co Inc on Thursday indicated that it would keep its animal health business as part of the company, in response to questions about its plans for the unit.

Cancer drug Keytruda powers Merck's profit beat, forecast raise

Merck & Co Inc said on Thursday sales of its blockbuster cancer immunotherapy Keytruda nearly doubled in the third quarter, helping the drugmaker beat profit estimates and lift its adjusted earnings forecast for the year.

UPDATE 2-Cancer drug Keytruda powers Merck's profit beat, forecast raise

Oct 25 Merck & Co Inc said on Thursday sales of its blockbuster cancer immunotherapy Keytruda nearly doubled in the third quarter, helping the drugmaker beat profit estimates and lift its adjusted earnings forecast for the year.

Select another date: